On April 28, 2022, Knowledge Ecology International (KEI) provided comments on the latest National Institutes of Health (NIH) Federal Register notice concerning licensing, the “Prospective Grant of an Exclusive Patent License: Development of Diagnostic for Imaging and Early Detection of… Continue Reading
ACTIV Partnership Records Records received via the KEI-NIH Freedom of Information Act (FOIA) lawsuit regarding an April 17, 2020 FOIA request for records relating to the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, the private-public partnership announced by the… Continue Reading
These are the additional comments to the WHO Public Hearing on a possible WHO treaty or other instrument on pandemic preparedness and response (KEI also provided oral testimony at the hearing, and filed earlier comments here). Luis Gil Abinader –… Continue Reading
Knowledge Ecology International (KEI) filed comments with the National Institutes of Health (NIH) on March 16, 2022 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor T-Cell Therapies (CAR-T) That are Specific to… Continue Reading
(More on this topic here: https://www.keionline.org/xtandi2021) On February 24, 2022, Senators Thom Tillis and Marsha Blackburn sent a letter to HHS Secretary Xavier Becerra (PDF copy). The letter refers to “petitions to march-in on a pharmaceutical product purely based on… Continue Reading
This is a letter from the three prostate cancer patient petitioners to HHS Secretary Becerra and Acting NIH Director Tabak, regarding the February 9, 2020 statement by Astellas on the Bayh-Dole march in and government rights case. The patient’s letter… Continue Reading
2016-Mar25-email-Re-Dir-Sig-Response-March-In-Letter 2016-Dec18-Email-Chain-Re-Reasonable-Pricing-Clauses 2016-Dec24-Email-Seeking-Help-Re-NCI-Criticism-Response 2016-Dec25-Email-Seeking-Help-NCI-Rebuttal 2016Mar30-Email-Sen-Sanders-Letter 2016Apr26-Email-Nader-Response 2016Jun27-Email-re-March-in Process 2017-Jan3-Email-Re-Help-NCI-Rebuttal 2017Jan5-Email-Regarding-Kite-License-Applicants 2017Apr24-Email-Chain-Re-Xtandi-Appeal 2017Nov20-email-helping-Allen 2017-Dec7-Email-Re-Placing-Op-Ed 2019Apr16-email-CAR T-information
Senators Elizabeth Warren (D-MA) and Angus King (I-ME) and Representative Lloyd Doggett (D-TX) wrote Secretary of HHS Xavier Becerra on February 17, 2022, urging him to move forward with the march-in petition by Robert Sachs, Clare Love and Eric Sawyer,… Continue Reading
(More on the Xtandi case here: https://www.keionline.org/xtandi2021) Astellas has issued a statement, dated February 9, 2022, on the Bayh-Dole Act and the petition to exercise march-in and government use rights in the prostate cancer drug Xtandi. It was brought to… Continue Reading
Revised February 14, 2022 Early 2000 UCLA claims work that led to the development of enzalutamide began at UCLA in early 2000. 2005 May 13, 2005. Priority date for the three patents in the Xtandi Orange Book. Patents 7709517, 8183274… Continue Reading